The near-total dilution of legacy Lisata shareholders (~2.39% ownership) and pivot to Marea's cardioendocrine pipeline make this a de facto reverse merger. Watch for stockholder vote on Series C conversion and Q4 2027 topline data from MAR001/005 Phase 2b and MAR002 Phase 2 trials — these are the next binary catalysts.
Price Chart
Executive Summary
Lisata Therapeutics acquires Marea Therapeutics in a stock-for-stock transaction and concurrently raises $225 million in a private placement financing. The combined company will focus on Marea's cardioendocrine pipeline (MAR001/005 for severe hypertriglyceridemia, MAR002 for acromegaly), with pre-transaction Lisata shareholders retaining only ~2.39% of the combined entity. This represents a near-total transformation of Lisata's business, effectively a reverse merger that pivots from oncology to cardioendocrine disease.
Key Facts
- Lisata acquires Marea in a stock-for-stock transaction; pre-transaction Lisata shareholders will own ~2.39% of the combined company on a fully-diluted, as-converted basis.
- Concurrent private placement financing raises $225 million from leading life sciences investors (RA Capital, Forbion, Third Rock, Alpha Wave, Perceptive, Sofinnova, Omega, Surveyor/Citadel, Columbia Threadneedle, Nantahala, Affinity, venBio, Rock Springs).
- Combined company will focus on MAR001/005 (Phase 2b for severe hypertriglyceridemia) and MAR002 (Phase 2 for acromegaly); both programs expected to report topline data in Q4 2027.
- Total pro forma shares outstanding ~396,315,542 on an as-converted basis (including Series C preferred).
- Marea equity holders will own ~59.54% and private placement investors ~38.07% of the combined company.
Financial Impact
$225 million gross proceeds from private placement; combined entity valued implicitly at ~$591M based on pro forma shares and $1.4914 per common share conversion price.
Risk Factors
- Legacy Lisata shareholders face massive dilution (~97.6% ownership loss).
- Clinical risk: MAR001/005 and MAR002 are still in Phase 2; topline data not expected until Q4 2027.
- Execution risk in integrating two companies and pivoting from oncology to cardioendocrine focus.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3364095 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | DEF 14A | $1.00 | awaiting T+60 | — | $1.06 (−6.00%) |
Oct 14, 2026 12d ago | 8-K | $1.07 | awaiting T+60 | — | $1.06 (−0.93%) |
Sep 17, 2026 5w ago | 8-K | $1.74 | awaiting T+60 | — | $1.06 (−39.08%) |
Sep 17, 2026 5w ago | Press Release | $1.74 | awaiting T+60 | — | $1.06 (−39.08%) |
Aug 4, 2026 12w ago | 8-K | $1.14 | awaiting T+60 | — | $1.06 (+7.02%) |
Jul 24, 2026 13w ago | 8-K | $1.67 $1.00 | ▲ +40.12% | ▲ +43.41% | $1.06 (+36.53%) |
Jul 17, 2026 14w ago | 8-K | $3.60 $1.05 | ▼ −70.79% | ▼ −75.48% | $1.06 (−70.51%) |
Jun 10, 2026 19w ago | Press Release | $3.61 $1.64 | ▼ −54.57% | ▼ −61.15% | $1.06 (−70.64%) |
Jun 9, 2026 20w ago | 8-K | $3.46 $1.57 | ▲ +54.62% | ▲ +58.44% | $1.06 (+69.36%) |
Jun 1, 2026 21w ago | 8-K | $3.58 $1.74 | ▲ +51.40% | ▲ +52.63% | $1.06 (+70.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers